{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:37:29Z","timestamp":1761061049817},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00120-020-01233-6","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T15:04:01Z","timestamp":1590678241000},"page":"784-789","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Immunonkologische Therapieoptionen des nicht-muskelinvasiven Urothelkarzinoms"],"prefix":"10.1007","volume":"59","author":[{"given":"M. W.","family":"Kramer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Gakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,28]]},"reference":[{"key":"1233_CR1","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","volume":"76","author":"M Babjuk","year":"2019","unstructured":"Babjuk\u00a0M, Burger\u00a0M, Comperat\u00a0EM et al (2019) European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) \u2013 2019 update. Eur Urol 76:639\u2013657","journal-title":"Eur Urol"},{"key":"1233_CR2","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/MOU.0000000000000548","volume":"28","author":"MP Mannas","year":"2018","unstructured":"Mannas\u00a0MP, Lee\u00a0T, Nykopp\u00a0TK et al (2018) A risk-stratified approach to the management of high-grade T1 bladder cancer. Curr Opin Urol 28:563\u2013569","journal-title":"Curr Opin Urol"},{"key":"1233_CR3","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3109\/21681805.2015.1040449","volume":"49","author":"G Gakis","year":"2015","unstructured":"Gakis\u00a0G, Todenhofer\u00a0T, Braun\u00a0M et\u00a0al (2015) Immunohistochemical assessment of lymphatic and blood vessel invasion in T1 urothelial carcinoma of the bladder. Scand J Urol 49:382\u2013387","journal-title":"Scand J Urol"},{"key":"1233_CR4","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"RJ Sylvester","year":"2002","unstructured":"Sylvester\u00a0RJ, van der Meijden\u00a0AP, Lamm\u00a0DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J\u00a0Urol 168:1964\u20131970","journal-title":"J Urol"},{"key":"1233_CR5","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","volume":"36","author":"VT Packiam","year":"2018","unstructured":"Packiam\u00a0VT, Lamm\u00a0DL, Barocas\u00a0DA et al (2018) An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results. Urol Oncol 36:440\u2013447","journal-title":"Urol Oncol"},{"key":"1233_CR6","doi-asserted-by":"publisher","first-page":"E284","DOI":"10.1111\/j.1464-410X.2010.09980.x","volume":"108","author":"W Jager","year":"2011","unstructured":"Jager\u00a0W, Thomas\u00a0C, Haag\u00a0S et al (2011) Early vs delayed radical cystectomy for \u2018high-risk\u2019 carcinoma not invading bladder muscle: delay of cystectomy reduces cancer-specific survival. BJU Int 108:E284\u2013288","journal-title":"BJU Int"},{"key":"1233_CR7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.436","author":"MO Grimm","year":"2020","unstructured":"Grimm\u00a0MO, Colombel\u00a0M et al (2020) Treatment of high-grade non-muscle invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: results of the phase III clinical trial (NIMBUS). J\u00a0Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2020.38.6_suppl.436","journal-title":"J Clin Oncol"},{"key":"1233_CR8","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10585-016-9807-9","volume":"33","author":"O Fahmy","year":"2016","unstructured":"Fahmy\u00a0O, Khairul-Asri\u00a0MG, Stenzl\u00a0A, Gakis\u00a0G (2016) The current status of checkpoint inhibitors in metastatic bladder cancer. Clin Exp Metastasis 33:629\u2013635","journal-title":"Clin Exp Metastasis"},{"key":"1233_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11934-015-0532-8","volume":"16","author":"J Mischinger","year":"2015","unstructured":"Mischinger\u00a0J, Comperat\u00a0E, Schwentner\u00a0C et\u00a0al (2015) Inflammation and cancer: what can we therapeutically expect from checkpoint inhibitors? Curr Urol Rep 16:59","journal-title":"Curr Urol Rep"},{"key":"1233_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-019-03065-2","author":"AM Aydin","year":"2020","unstructured":"Aydin\u00a0AM, Baydar\u00a0DE, Hazir\u00a0B et al (2020) Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy. World J Urol. https:\/\/doi.org\/10.1007\/s00345-019-03065-2","journal-title":"World J Urol"},{"key":"1233_CR11","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ebiom.2019.10.058","volume":"50","author":"BN Song","year":"2019","unstructured":"Song\u00a0BN, Kim\u00a0SK, Mun\u00a0JY et al (2019) Identification of an immunotherapy-responsive molecular subtype of bladder cancer. EBioMedicine 50:238\u2013245","journal-title":"EBioMedicine"},{"key":"1233_CR12","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1158\/1078-0432.CCR-19-1920","volume":"26","author":"M Kates","year":"2020","unstructured":"Kates\u00a0M, Matoso\u00a0A, Choi\u00a0W et al (2020) Adaptive immune resistance to intravesical BCG in non-muscle invasive bladder cancer: implications for prospective BCG-unresponsive trials. Clin Cancer Res 26:882\u2013891","journal-title":"Clin Cancer Res"},{"key":"1233_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.7_suppl.350","author":"AV Balar","year":"2019","unstructured":"Balar\u00a0AV, Uchio\u00a0EM et al (2019) Keynote 057: phase II trial of pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Gu\u00e9rin (BCG). J\u00a0Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2019.37.7_suppl.350","journal-title":"J Clin Oncol"},{"key":"1233_CR14","doi-asserted-by":"publisher","first-page":"e1167","DOI":"10.1016\/j.juro.2018.03.099","volume":"199","author":"R Dickstein","year":"2018","unstructured":"Dickstein\u00a0R, Cowan\u00a0B (2018) Phase 3 study of vicinium in BCG-unresponsive non-muscle invasive bladder cancer: initial results. J\u00a0Urol 199:e1167","journal-title":"J Urol"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-020-01233-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-020-01233-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-020-01233-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T23:51:16Z","timestamp":1622159476000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-020-01233-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1233"],"URL":"https:\/\/doi.org\/10.1007\/s00120-020-01233-6","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,28]]},"assertion":[{"value":"28 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.W.\u00a0Kramer: (letzte 3\u00a0Jahre) MSD: Advisory Board, Vortragst\u00e4tigkeit; Ipsen Pharma: Reise\u2011\/Kongressunterst\u00fctzung; Roche: Advisory Board, Vortragst\u00e4tigkeit; Merck: Vortragst\u00e4tigkeit; BMS: Advisory Board, Vortragst\u00e4tigkeit und G.\u00a0Gakis: (letzte 3\u00a0Jahre) MSD: Advisory Board, Vortragst\u00e4tigkeit; Ipsen Pharma: Forschungsf\u00f6rderung, Vortragst\u00e4tigkeit, Reise\u2011\/Kongressunterst\u00fctzung; Erbe Elektromedizin GmbH: Vortragst\u00e4tigkeit; medac GmbH: Vortragst\u00e4tigkeit; Leo Pharma GmbH: Advisory Board, Vortragst\u00e4tigkeit.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}